PlainPharmaWatch

CMS Open Payments · Program Year 2024

AstraZeneca Pharmaceuticals LP

AstraZeneca Pharmaceuticals LP reported $428,167,709.31 in payments to 858,609 physicians and teaching hospitals across 864,383 transactions.

$428.2M
Total payments
864,383
Transactions
858,609
Recipients
+$7.5M
General Payments vs PY2023

AstraZeneca Pharmaceuticals LP reported $428,167,709.31 in payments to 858,609 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #7 of 1,925 reporting manufacturers (3.1% of all US industry payments), averaging $498.68 per recipient across 11 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

The verdict

AstraZeneca Pharmaceuticals LP pairs top-1% payment volume with an unusually diversified payment pattern across a wide recipient base.

#7
of 1,925 companies
3.1%
of all US industry payments
0.0%
paid to its single top recipient
11
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

AstraZeneca Pharmaceuticals LP's CMS-reported General Payments increased by $7.5M (+13.1%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ASTRAZENECA PHARMACEUTICALS LPPY2023: ASTRAZENECA PHARMACEUTICALS LPPY2024: AstraZeneca Pharmaceuticals LP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$57.2MPY2024$64.7M
PY2023
$57,247,929.30
PY2024
$64,724,186.83

How AstraZeneca Pharmaceuticals LP ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

AstraZeneca Pharmaceuticals LP's total vs. every reporting company

CMS Open Payments, Program Year 2024

$428,167,709 Top 1% higher than 99% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Below this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Below this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Below this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). This entry sits in this band. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for AstraZeneca Pharmaceuticals LP

Rank #7 of 1,925 companies in CMS Open Payments for 2024 belongs to AstraZeneca Pharmaceuticals LP, which reported $428,167,709.31 across 864,383 transactions to 858,609 recipients - a top-tier 3.1% share of all industry payments reported nationwide for the year. Averages work out to $495.34 per transaction and $498.68 per recipient.

The 11-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $28.4M, accounting for 6.6% of the company's reported total and 12,785 transactions.

General Payment Breakdown by Type

AstraZeneca Pharmaceuticals LP made 11 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $28.4M, 6.6% of the company's reported total.

How AstraZeneca Pharmaceuticals LP divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$28.4M2. Food and Beverage$17.4M3. Consulting Fee$9.5M4. Grant$4.3M5. Travel and Lodging$3.3M6. Space Rental or Facility …$1.4M7. Gift$187.0K8. Education$113.3K9. Royalty or License$92.5K10. Compensation for Faculty…$56.0K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $28.4M 12,785
Food and Beverage $17.4M 824,499
Consulting Fee $9.5M 4,937
Grant $4.3M 220
Travel and Lodging $3.3M 10,541
Space Rental or Facility Fees $1.4M 615
Gift $187.0K 11
Education $113.3K 4,747
Royalty or License $92.5K 1
Compensation for Faculty or Speaker (Medical Education) $56.0K 130
Charitable Contribution $38.1K 123

Recipient Concentration in General Payments

The five largest recipient relationships account for $3,731,100.52 (5.8%) of $64,724,186.83 in this company's General Payments records across 138,305 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for AstraZeneca Pharmaceuticals LP

The five named recipients with the highest reported General Payments from this company

National Jewish Health$2.4MHoward University Hospital$387.6KOhsu Hospital And Clinics$376.4KEmory University Hospital$278.9KTufts Medical Center$260.0K
  1. 1

    National Jewish Health

    $2,428,146.00 across 18 reported transactions

  2. 2

    Howard University Hospital

    $387,650.00 across 4 reported transactions

  3. 3

    Ohsu Hospital And Clinics

    $376,360.00 across 7 reported transactions

  4. 4

    Emory University Hospital

    $278,944.52 across 14 reported transactions

  5. 5

    Tufts Medical Center

    $260,000.00 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $495.34. Average per recipient: $498.68.

Total Amount

$428,167,709.31

Avg per Transaction

$495.34

Avg per Recipient

$498.68

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

AstraZeneca Pharmaceuticals LP Share

3.1%

#7 by total payments

Frequently Asked Questions

How much did AstraZeneca Pharmaceuticals LP pay to physicians and hospitals in 2024?
AstraZeneca Pharmaceuticals LP made $428,167,709.31 in payments to physicians and hospitals in Program Year 2024, across 864,383 individual transactions. This represents 3.1% of all industry payments reported to CMS Open Payments.
How many physicians received payments from AstraZeneca Pharmaceuticals LP?
858,609 physicians and teaching hospitals received payments from AstraZeneca Pharmaceuticals LP in 2024, averaging $498.68 per recipient.
What types of payments did AstraZeneca Pharmaceuticals LP make?
11 categories of general payment make up AstraZeneca Pharmaceuticals LP's reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $28.4M, representing 6.6% of the company's reported total.
How does AstraZeneca Pharmaceuticals LP rank among pharmaceutical companies?
Out of 1,925 companies in the CMS Open Payments database for 2024, AstraZeneca Pharmaceuticals LP ranks #7 by total payment amount.
What is the average payment size from AstraZeneca Pharmaceuticals LP?
AstraZeneca Pharmaceuticals LP's 864,383 transactions to 858,609 recipients in 2024 averaged $495.34 per transaction.
Where does the payment data for AstraZeneca Pharmaceuticals LP come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download AstraZeneca Pharmaceuticals LP's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.